How much is the domestic launch and medical insurance price of Regorafenib?
Regorafenib (Regorafenib) has been launched in China and has been included in the scope of medical insurance, which means that eligible patients can purchase it at domestic hospitals or pharmacies, and some of the costs can be reimbursed through medical insurance. At present, the price of regorafenib in China is about four to five thousand yuan, but the specific price and medical insurance reimbursement ratio may vary depending on regional and hospital policies. Therefore, it is recommended that patients consult the local hospital pharmacy or relevant medical insurance department before purchasing to obtain the most accurate price information and reimbursement policies.

In addition to domestic original drugs, Regorafenib also has two options: original drugs and generic drugs abroad. The original medicine mainly comes from Türkiye, and its price is relatively low, about more than 1,000 yuan. Generic drugs come from countries such as Laos, India, and Bangladesh, and their prices range from a few hundred yuan to more than a thousand yuan. It is worth noting that although the ingredients of original drugs and generic drugs are basically the same, there may still be certain differences in quality and effect, so careful consideration is needed when choosing.
Regorafenib As a targeted drug, it plays an important role in the treatment of advanced cancer. Regorafenib, which is marketed in China and included in medical insurance, is relatively expensive, but patients can reimburse part of the cost through medical insurance. At the same time, foreign original drugs and generic drugs provide other options, but patients need to weigh between quality and price and make appropriate choices based on their own conditions and doctor's recommendations.
Regorafenib , as a targeted drug, brings new treatment options to patients with advanced cancer. Its emergence provides new hope and opportunities for tumor patients who were once unable to be controlled through traditional treatments. However, specific treatment options and methods of use need to be fully discussed and considered by both patients and doctors to formulate the most appropriate treatment strategy.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)